Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Capital expenditures
Arrowhead Pharmaceuticals (ARWR) capital expenditures by quarter
Arrowhead Pharmaceuticals' capital expenditures were $2.6M in Q2 FY26 (second quarter fiscal 2026), +19% from Q1 FY26. Over the last 4 quarters it ranged from $2.1M (Q1 FY26) to $7.5M (Q4 FY25).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 FY26 | $2.6M | +19% | -52% |
| Q1 FY26 | $2.1M | -71% | — |
| Q4 FY25 | $7.5M | +41% | — |
| Q2 FY25 | $5.3M | — | — |
Q2 FY26 at a glance
Arrowhead Pharmaceuticals, Q2 FY26: revenue $73.7M (-86% year over year), operating margin -191.6%, net loss $138M, operating cash flow $84.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arrowhead Pharmaceuticals' capital expenditures?
Arrowhead Pharmaceuticals' capital expenditures were $2.6M in Q2 FY26 (second quarter fiscal 2026), +19% from Q1 FY26.
How has Arrowhead Pharmaceuticals' capital expenditures changed?
Over the last 4 quarters it ranged from $2.1M (Q1 FY26) to $7.5M (Q4 FY25).
Q2 FY26 results → · How Arrowhead Pharmaceuticals makes money →